Serous carcinoma

Gastrointestinal, pancreas, biliary, lung, transitional cell, sweat glands, mucosal squamous cell, mucinous carcinomas of female GU tract, medullary carcinoma of thyroid Breast, squamous cell, endometrioid, Brenner tumor Renal cell, hepatocellular, prostate, follicular thyroid, adrenal cortical, serous carcinomas of female GU tract, embryonal, yolk sac, mesothelioma... 

Staebler A, Karberg B, Behm J et al. Chromosomal losses of regions on 5q and lack of high-level amplifleations at 8q24 are assoeiated with favorable prognosis for ovarian serous carcinoma. Genes... 

Recently, Caduff et al. (1999) have evaluated abnormalities in p53 and Ki-ra.v in malignant and borderline ovarian tumors of various histological types in paraffin-embedded tissues. The patterns of these genetic alterations in borderline and malignant neoplasms were compared and correlated with cell type and stage. This preliminary molecular analysis suggests that serous borderline tumors have the same molecular features usually associated with malignancy but are unlikely to represent a precursor of invasive serous carcinoma. On the other hand, mucinous borderline tumors may represent a precursor or variant of mucinous carcinoma of the ovary. 

Negative Renal cell, hepatocellular, prostate, follicular thyroid, adrenal cortical, serous carcinomas of female GU tract, embryonal, yolk sac, mesothelioma... 

A second, independent study repeated the visual inspection analysis and compared the sensitivities and specificities obtained using visual inspection and a precursor of the SCS analysis on the same data set.43 Biopsy samples of postmenopausal ovaries, benign ovarian neoplasms and ovarian cancers ( 0.5 g) were obtained during surgery. The histological types of these samples were normal (19), benign tumour (3), borderline tumour (3), serous carcinoma (13), endometroid carcinoma (17), mixed epithelial carcinoma (3), and small cell carcinoma (4). Proton MRS measurements were performed at 37°C at 8.5 T.43... 

Yakirevich, E. Sabo, E. Naroditsky, I. Sova, Y. Lavie, O. Resnick, M. B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006, 100, 152-159. 

Ovarian serous carcinomas demonstrate diffuse strong WTl nuclear expression. 

The majority of endometrial serous carcinomas are negative for WTl positive cases generally show patchy staining. 

Pitfaii CK5/6+ in squamous and transitionai ceil carcinomas WT1+ in ovarian papiiiary serous carcinoma... 

Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004 44 109-115. 

Goldstein NS, Uzieblo A. WTl immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002 117 541-545. 

Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian mbe, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003 22 374-377. 

Tong GX, Chiriboga L, Hamele-Bena D, Borczuk AC. Expression of PAX2 in papillary serous carcinoma of the ovary immunohistochemical evidence of fallopian tube or secondary Mullerian system origin Mod Pathol. 2007 20 856-863. 

D2-40, a clone of podoplanin, is a recently developed commercially available antibody directed against the M2A antigen, a 40,000-kD sialoglycoprotein associated with germ cells and lymphatic endothelium. Chu and colleagues evaluated 53 cases of mesothelioma, 28 cases of reactive pleural tissue, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and 7 cases of urothelial carcinoma. The authors found D2-40 expression in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) reactive pleural tissues, and 17 of 26 (65%) ovarian serous carcinomas. They did not find D2-40 in the other tumors examined. The authors also observed that the neoplastic cells immunostained in a cell membrane distribution. 

Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women A clinicopathologic and immunohistochemical study. Cancer. 1995 76 429-436. 

Hwang H, Quermeville L, Yaziji H, et al. Wilms tumor gene product Sensitive and contextually specific marker of serous carcinoma of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004 12 122-126. 

Mills SE, Andersen WA, Fechner RE, et al. Serous surface papillary carcinomas A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol. 1988 12 827-834. 

Ovarian mucinous Ca Prostatic Ca Ovarian serous carcinoma Primary seminal vesicle Ca... 

Overexpression of the p53 tumor suppressor protein is seen in more than 80% of uterine serous carcinomas and in their putative precursor lesion, endometrial intraepithelial carcinoma The most com-... 

FIGURE 18.14 Markers of emerging importance in distinguishing uterine endometrioid carcinoma and uterine serous carcinoma include p33, p-catenin, and PTEN. While serous carcinomas characteristically overexpress p53 (A), endometrioid adenocarcinomas, especially when gland-forming, frequently express estrogen receptors (B), commonly show at least focal nuclear and cytoplasmic staining with anti-P-catenin (C), and lose expression of PTEN (D). 

It is easy to recognize endometrial serous carcinoma when it is tumor forming and present in its characteristic papillary form with bizarre tumor cell nuclei. However, endometrial serous carcinoma can be difficult to diagnose... 

Einally, it should be noted that while many serous adenocarcinomas of endometrium resemble ovarian serous carcinomas, there are some important differences. We will discuss these differences in the Ovary section. The most important of these is infrequent WTl expression in endometrial serous carcinomas (seen in at most 20% to 30% of such cases) and the very common diffuse nuclear expression of WTI in ovarian, tubal, and primary peritoneal examples (at least 70% to 80% of such cases). 

---